A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. - Wikidata - awgldk - TriplyDB

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q33402939

about

Systematic review of dasatinib in chronic myeloid leukemia Chronic myeloid leukemia: reminiscences and dreams European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Imatinib in chronic myeloid leukemia: an overview Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU Automated synthesis and visualization of a chemotherapy treatment regimen network.Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Chronic Myelogenous Leukemia, Version 1.2014 The role of dasatinib in the management of chronic myeloid leukemia Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).The choice of first-line chronic myelogenous leukemia treatment.How we will treat chronic myeloid leukemia in 2016.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.Is imatinib still the best choice as first-line oral TKI.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.Chronic myeloid leukemia: overview of new agents and comparative analysis.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.How I treat newly diagnosed chronic myeloid leukemia in 2015.A review of the European LeukemiaNet recommendations for the management of CML.Update on emerging treatments for chronic myeloid leukemia.Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.New Methodologies in the Molecular Monitoring of CML.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.

P2860

Q24596026-B5FF7275-AE6C-468C-95CC-A473C1101B58 Q26748769-4F53EC6E-0947-484E-835D-9D30DD10A406 Q26749324-BF63336F-B27E-49A7-B081-011446CAB711 Q26865086-0BDF6294-7012-43FD-B145-B57B4647DF28 Q28079372-53E9A1DF-85AF-46E0-9747-220A1A6B37BB Q28086893-B6C63EB5-7B09-4692-8F83-7A204598457C Q33822231-72A769FB-31C7-43DC-9023-4C569B221B90 Q33914049-EAB0C3F1-AECD-4756-BCF0-BFDD1CD4D7E0 Q34022596-993987A7-E78C-4A9C-B6EB-0F04EA8BF170 Q34417824-801DBCA1-3BEC-40BD-B1C3-0B5EE08F00A7 Q34522810-D37DA7F9-17E9-4C16-BB71-6270604F1449 Q35087994-8AD82187-58AF-4FEC-A600-4EF3B3706F3E Q35194464-A83C0BCB-B84C-45D8-B163-B8290E550D3D Q35221071-27AC420D-7768-407B-B5B3-1EC65F0BB780 Q35269378-C48E7286-FC56-4874-A19A-951E4FC8FFAA Q35735663-1A339E2D-3195-4C5C-971C-8505BC3D7080 Q36546004-8DB1E792-6E0E-444F-8265-7F4A5F6E553C Q36624496-7E494A15-750C-4233-B120-6C8A72238F6A Q37026032-35592884-35AE-402F-8795-82537724294F Q37365606-A9C7A679-1127-4750-AA4A-A39A8EC97FD8 Q37427140-074D7FAE-F3F8-4ABE-8BEC-4178F7195F68 Q37654034-366454ED-D79D-4062-ADD0-EC72911107A4 Q37696776-82A125E9-AA78-497E-8492-C1F87510E6AC Q38095386-A977AA08-DE3E-42F0-B358-700C6CA6255B Q38097728-55B484CD-2378-4736-B5DA-D0553E985C4F Q38128723-39B30F22-DF70-437A-BC37-D9D958D24B00 Q38139571-43D8A968-DD19-4A9E-862A-A52E716D21A9 Q38148233-7AC2B364-7D26-4393-A439-2EBA258820FB Q38149613-39780ADF-0CFF-45A9-BD95-AFD57FEE5146 Q38183422-E4874896-8AFE-40FE-9406-92FEF77C2531 Q38262877-ED7D195D-4E02-42C0-9EE7-A1655DD49BA9 Q38265086-87A1493B-1D8B-47B0-B909-358BDD7610D2 Q38392676-12F38023-A74D-4A9C-9337-3667F5A15522 Q38397515-DC2B9241-EB5E-4BC2-9597-2136A672FB3F Q38604104-B342C4A8-B237-422D-A51E-038FA5826937 Q38631124-D78CE383-E00F-4FD8-BCD4-7EFBA3C5A9BE Q38685803-86DAD3B8-2C38-4FBC-82F9-22CB9B90E584 Q38748512-A3A107ED-5DD0-43F8-A478-0D150D441B51 Q38762203-E56D41CB-2AF3-4A0B-A552-8693826AEE46 Q38802249-AC14E689-CA6D-4A78-AD56-8B6A1B69B20D

P2860

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

http://www.wikidata.org/entity/Q33402939

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@ast

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@en

type

label

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@ast

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@en

prefLabel

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@ast

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@en

P1433

Q33402939-A242606A-A758-4452-B58B-522585D2C9A4

P1476

Q33402939-A52E9C9D-BA57-4720-83E9-22BD5792B900

P2093

Q33402939-42F95100-FD48-483A-9B7C-06EB42CF1AB5

Q33402939-5B4397B5-221D-43AB-83CA-A2E0ADED3EC3

Q33402939-818472B0-4B8A-4CE2-9101-D73AF6DBCBF9

Q33402939-A095F6E4-5278-42AE-8D39-8C64831B7AAB

Q33402939-AE3A9509-9F99-45CA-BF73-ECC2DD3CAB04

Q33402939-B596A6AE-EF97-46A1-A1E3-67A441820387

Q33402939-CA1696F6-A8A5-4B76-A5B8-A26480CEBFF8

P2860

Q33402939-00E39E29-7876-46FC-B750-8DD753689076

Q33402939-1F5CCF4C-E0B5-4043-8145-3E6E811E670A

Q33402939-2080CBA0-0B87-4975-B520-4EA6C4EBFD4A

Q33402939-2CE2BD2D-9A96-4AF7-82CA-EB0B6E79600E

Q33402939-408A73FF-4706-4A58-A8C5-2C771D6D6210

Q33402939-51C98E9F-3ECB-4725-A2F3-6FCA98B6577E

Q33402939-53E414FE-89E5-4483-B279-978128AD616F

Q33402939-61200777-B18D-4E28-ABC5-B87A3304E8A4

Q33402939-61465043-A1A6-4A19-AE7C-EF5FDE56EA3E

Q33402939-6DE970BE-505B-4F1A-9D86-D97F9AF197DA

P304

Q33402939-181B4C11-EDE4-4DD5-948A-5F5CB3C4D280

P31

Q33402939-DA4B0CF8-8E51-463C-B339-9D4EBB0E1519

P356

Q33402939-26C9C066-FD09-45BF-A4D1-59EF31C86A65

P407

Q33402939-B32A087D-BE93-4348-878C-FE2681631A49

P433

Q33402939-CBD63AB3-0735-4D2E-9A2B-8374965947F7

P478

Q33402939-F8C57538-A79C-48F7-87E7-A0D272F1E2E9

P50

Q33402939-02456E67-01A7-4614-ADD8-D0EE61005664

Q33402939-3FCBAC97-4486-4C6A-9671-83A70381672E

Q33402939-82123440-7D40-4F23-8A45-8E535FE8E948

Q33402939-9794D6FA-E6DE-48FF-8F76-8470A60D62D4

Q33402939-AC9D2B1F-8F48-4CCC-AAE2-0AD47120033C

Q33402939-BA576590-FC47-4FBD-97C9-E2D70C2FA580

Q33402939-BBD4FF95-A5E9-4C68-8D10-7C8B6DE075C0

Q33402939-CB298063-B6F1-4495-9045-56BA7D214477

P577

Q33402939-FFE5012D-E687-4063-837B-63EDBEB792C3

P5875

Q33402939-9CE3C6DC-02B1-4733-AE13-3F0BC8848250

P698

Q33402939-FF135C6A-ACC5-4BB1-997C-2FA5AAA69008

P921

Q33402939-4C274448-7569-4BC9-9241-48FE580E4B2F

Q33402939-D124CE69-EFDF-4F95-A7F7-7DEC1A6251E8

P932

Q33402939-B1ABAE68-7CE0-4515-BA82-A15D5DFDC7DA

P356

BLOOD-2012-02-410688

P1433

P1476

A randomized trial of dasatini ...... hase chronic myeloid leukemia.

@en

P2093

A Robert Turner

http://www.w3.org/2001/XMLSchema#string

Greg Malnassy

http://www.w3.org/2001/XMLSchema#string

Jeff Lipton

http://www.w3.org/2001/XMLSchema#string

Jerald P Radich

http://www.w3.org/2001/XMLSchema#string

Kenneth J Kopecky

http://www.w3.org/2001/XMLSchema#string

Michael Deininger

http://www.w3.org/2001/XMLSchema#string

Wendy Stock

http://www.w3.org/2001/XMLSchema#string

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Chronic myeloid leukemia.

The biology of chronic myeloid leukemia.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

P304

3898-3905

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-02-410688

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Brian J. Druker

Martha Wadleigh

Suzanne Kamel-Reid

Richard A. Larson

Peter D. Emanuel

Martin S Tallman

Elisabeth Paietta

Frederick R. Appelbaum

P577

2012-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230723970

http://www.w3.org/2001/XMLSchema#string

P698

22915637

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

3496952

http://www.w3.org/2001/XMLSchema#string